Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV.
AIDS defining cancer
HIV
body mass index
incidence
infection
non-AIDS defining cancer
smoking
trends
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Jul 2023
15 Jul 2023
Historique:
received:
08
06
2023
revised:
03
07
2023
accepted:
07
07
2023
medline:
29
7
2023
pubmed:
29
7
2023
entrez:
29
7
2023
Statut:
epublish
Résumé
Despite cancer being a leading comorbidity amongst individuals with HIV, there are limited data assessing cancer trends across different antiretroviral therapy (ART)-eras. We calculated age-standardised cancer incidence rates (IRs) from 2006-2021 in two international cohort collaborations (D:A:D and RESPOND). Poisson regression was used to assess temporal trends, adjusted for potential confounders. Amongst 64,937 individuals (31% ART-naïve at baseline) and 490,376 total person-years of follow-up (PYFU), there were 3763 incident cancers (IR 7.7/1000 PYFU [95% CI 7.4, 7.9]): 950 AIDS-defining cancers (ADCs), 2813 non-ADCs, 1677 infection-related cancers, 1372 smoking-related cancers, and 719 BMI-related cancers (groups were not mutually exclusive). Age-standardised IRs for overall cancer remained fairly constant over time (8.22/1000 PYFU [7.52, 8.97] in 2006-2007, 7.54 [6.59, 8.59] in 2020-2021). The incidence of ADCs (3.23 [2.79, 3.72], 0.99 [0.67, 1.42]) and infection-related cancers (4.83 [4.2, 5.41], 2.43 [1.90, 3.05]) decreased over time, whilst the incidence of non-ADCs (4.99 [4.44, 5.58], 6.55 [5.67, 7.53]), smoking-related cancers (2.38 [2.01, 2.79], 3.25 [2.63-3.96]), and BMI-related cancers (1.07 [0.83, 1.37], 1.88 [1.42, 2.44]) increased. Trends were similar after adjusting for demographics, comorbidities, HIV-related factors, and ART use. These results highlight the need for better prevention strategies to reduce the incidence of NADCs, smoking-, and BMI-related cancers.
Identifiants
pubmed: 37509301
pii: cancers15143640
doi: 10.3390/cancers15143640
pmc: PMC10377704
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Gilead Sciences (United States)
ID : CO-EU-311-4339
Organisme : ViiV Healthcare (United Kingdom)
ID : 207709
Organisme : Danish National Research Foundation
ID : DNRF126
Organisme : Please see manuscript for full funding details
ID : NA
Organisme : MSD (United States)
ID : LKR196747
Références
N Engl J Med. 2007 Apr 26;356(17):1723-35
pubmed: 17460226
Clin Infect Dis. 2010 May 15;50(10):1387-96
pubmed: 20380565
Curr HIV/AIDS Rep. 2020 Apr;17(2):138-150
pubmed: 32072466
JAMA. 2017 Jun 20;317(23):2402-2416
pubmed: 28632866
J Int AIDS Soc. 2021 Apr;24(4):e25702
pubmed: 33838004
AIDS. 2014 Sep 10;28(14):2109-18
pubmed: 25265077
Microorganisms. 2020 Jul 31;8(8):
pubmed: 32752044
Lancet HIV. 2018 Jun;5(6):e291-e300
pubmed: 29731407
Proc Assoc Am Physicians. 1999 Nov-Dec;111(6):573-80
pubmed: 10591086
Lancet HIV. 2017 Nov;4(11):e495-e504
pubmed: 28803888
J Acquir Immune Defic Syndr. 2015 Apr 15;68(5):568-77
pubmed: 25763785
Ann Intern Med. 2015 Mar 3;162(5):335-44
pubmed: 25732274
AIDS Res Ther. 2018 Dec 12;15(1):26
pubmed: 30541577
Am J Epidemiol. 2013 Jan 15;177(2):116-25
pubmed: 23287403
Prev Med. 2018 Jun;111:231-234
pubmed: 29550303
Cancers (Basel). 2019 Feb 10;11(2):
pubmed: 30744199
Clin Infect Dis. 2004 Nov 1;39(9):1380-4
pubmed: 15494916
Curr Opin Oncol. 2007 Sep;19(5):446-51
pubmed: 17762569
AIDS. 2003 May 23;17(8):1179-93
pubmed: 12819520
Clin Infect Dis. 2019 Feb 1;68(4):650-657
pubmed: 29912335
Curr Opin Oncol. 2012 Sep;24(5):506-16
pubmed: 22759737
Ann Intern Med. 2015 Oct 6;163(7):507-18
pubmed: 26436616
J Clin Oncol. 2009 Feb 20;27(6):884-90
pubmed: 19114688
N Engl J Med. 2015 Aug 27;373(9):795-807
pubmed: 26192873
PLoS One. 2015 Dec 02;10(12):e0142966
pubmed: 26629701
IARC Sci Publ. 1987;(82):1-406
pubmed: 3329634
Open Forum Infect Dis. 2022 Jan 19;9(3):ofac029
pubmed: 35198646
Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):16-27
pubmed: 26667886
Br J Cancer. 2010 Jul 27;103(3):416-22
pubmed: 20588274
J Acquir Immune Defic Syndr. 2020 Mar 1;83(3):240-250
pubmed: 31923088
Lancet HIV. 2023 Feb;10(2):e97-e106
pubmed: 36640800
J Natl Cancer Inst. 2021 Nov 29;113(12):1648-1669
pubmed: 34240195
AIDS. 2022 Dec 1;36(15):2107-2119
pubmed: 35848573
AIDS. 2021 Apr 1;35(5):747-757
pubmed: 33306554
Lancet. 2016 Apr 2;387(10026):1377-1396
pubmed: 27115820
N Engl J Med. 2016 Aug 25;375(8):794-8
pubmed: 27557308
Ann Oncol. 2013 Feb;24(2):301-308
pubmed: 22910838
AIDS. 2012 Nov 13;26(17):2223-31
pubmed: 22951631
Int J Cancer. 2012 Jun 15;130(12):2990-6
pubmed: 21796633
Open Forum Infect Dis. 2020 May 26;7(6):ofaa195
pubmed: 32577427
Curr HIV/AIDS Rep. 2018 Apr;15(2):162-171
pubmed: 29504063
Lancet HIV. 2021 Nov;8(11):e711-e722
pubmed: 34555326
Ann Oncol. 2013 Oct;24(10):2651-2656
pubmed: 23884440
AIDS Res Hum Retroviruses. 2016 Jan;32(1):50-8
pubmed: 26352511
AIDS. 2016 Jul 17;30(11):1795-806
pubmed: 27064994
CA Cancer J Clin. 2023 Jan;73(1):17-48
pubmed: 36633525
AIDS Res Hum Retroviruses. 2013 Aug;29(8):1097-104
pubmed: 23581483
J Natl Cancer Inst. 2000 Nov 15;92(22):1823-30
pubmed: 11078759
Ann Intern Med. 2021 Jun;174(6):768-776
pubmed: 33721519
Lancet. 2014 Jul 19;384(9939):241-8
pubmed: 25042234
AIDS. 2018 Feb 20;32(4):513-521
pubmed: 29239891
AIDS. 2013 Jun 1;27(9):1433-41
pubmed: 23945504
BMC Infect Dis. 2020 Feb 14;20(1):144
pubmed: 32059635
HIV Med. 2013 Apr;14(4):195-207
pubmed: 22998068
Int J Cancer. 2008 Jul 1;123(1):187-94
pubmed: 18435450
Cancer. 2010 Dec 1;116(23):5507-16
pubmed: 20672354
Stat Med. 1991 Mar;10(3):457-62
pubmed: 2028128
Surg Clin North Am. 2020 Jun;100(3):469-481
pubmed: 32402294
AIDS. 2009 Nov 13;23(17):2337-45
pubmed: 19741479
Br J Cancer. 2015 Feb 3;112(3):580-93
pubmed: 25422909
AIDS. 2015 Jan 14;29(2):221-9
pubmed: 25426809
BMC Infect Dis. 2013 Oct 09;13:471
pubmed: 24106926